Top 10 Insider Purchases Last Month

7. Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD)

Total value of insider purchases in February: $23,424,672.00

Market capitalization: $218.12 million

Seventh among 10 stocks with the highest value of insider purchases in February is a clinical-stage biopharma company Aardvark Therapeutics. The San Diego, California-based company is dedicated to developing small-molecule therapies aimed at activating innate homeostatic pathways to address metabolic disorders.

The company’s lead product, ARD-101, is designed to target receptors found on enteroendocrine cells in the gut lumen, which play a vital role in gut-brain signaling. ARD-101 is currently in Phase III trials for treating hyperphagia associated with Prader-Willi Syndrome and Phase II trials for hyperphagia linked to acquired hypothalamic obesity.

Aardvark went public in February, and during its IPO, four insiders bought a total of $23.42 million worth of Aardvark shares at a price of $16 per share. Since then, its shares lost 28.72% and the stock is now trading at $10.20 per share.

Four analysts have given Aardvark stock an average rating of “Strong Buy,” writes StockAnalysis. The 12-month price target is set at $30.50.